Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Rhea-AI Summary

Mirum Pharmaceuticals (NASDAQ: MIRM) has scheduled its third quarter 2024 financial results announcement and conference call for November 12, 2024. The conference call will take place at 8:30 a.m. ET / 5:30 a.m. PT, accessible via toll-free dial-in for U.S. participants and international lines. A webcast option will be available through the company's website, with a replay accessible for 30 days following the event.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report third quarter 2024 financial results on November 12, 2024. Mirum will also host a conference call to discuss the third quarter 2024 financial results and recent corporate progress.

Conference call details:

Tuesday, November 12, 2024

8:30 a.m. ET / 5:30 a.m. PT

Dial-in:

U.S./Toll-Free: + 1 833 470 1428

International: + 1 404 975 4839

Passcode: 749358

You may also access the call via webcast by visiting the Events & Presentations section on Mirum’s website. A replay of this webcast will be available for 30 days.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CHENODAL® (chenodiol) tablets.

LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum is also initiating the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms or liver disease. CHENODAL has received medical necessity recognition by the FDA to treat patients with cerebrotendinous xanthomatosis (CTX).

Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis. Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Lastly, chenodiol, has been evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX, with positive topline results reported in 2023. Mirum has submitted a new drug application with the FDA for the approval of chenodiol to treat CTX in the U.S.

To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter (X).

View source version on businesswire.com: https://www.businesswire.com/news/home/20241104008489/en/

Investors:

Andrew McKibben

ir@mirumpharma.com

Media:

Erin Murphy

media@mirumpharma.com

Source: Mirum Pharmaceuticals, Inc.

FAQ

When will Mirum Pharmaceuticals (MIRM) release Q3 2024 earnings?

Mirum Pharmaceuticals will release its third quarter 2024 financial results on November 12, 2024.

What time is Mirum Pharmaceuticals' (MIRM) Q3 2024 earnings call?

The earnings conference call is scheduled for Tuesday, November 12, 2024, at 8:30 a.m. ET / 5:30 a.m. PT.

How can I access Mirum Pharmaceuticals' (MIRM) Q3 2024 earnings call?

You can access the call via U.S. toll-free number (1-833-470-1428), international number (1-404-975-4839) with passcode 749358, or through the webcast on Mirum's website.